- Associated Press•11 days ago
On a per-share basis, the Montreal-based company said it had a loss of 71 cents. The drug developer posted revenue of $304,000 in the period. For the year, the company reported that its loss narrowed to ...
- Business Wire•11 days ago
Aeterna Zentaris Inc. , a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology, today reported financial and operating results for the fourth quarter and year ended December 31, 2016.
- Business Wire•20 days ago
Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen™
Aeterna Zentaris Inc. announced today that the Pediatric Committee of the European Medicines Agency agreed to the Company’s Pediatric Investigation Plan for Macrilen™ and agreed that the Company may defer conducting the PIP until after it files a Marketing Authorization Application seeking marketing authorization for the use of Macrilen™ for the evaluation of adult growth hormone deficiency.
AEZS : Summary for Aeterna Zentaris Inc. - Yahoo Finance
Aeterna Zentaris Inc. (AEZS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.00 x 1000|
|Ask||7.00 x 100|
|Day's Range||2.75 - 2.92|
|52 Week Range||2.35 - 5.59|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.20|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|